Article Text

Download PDFPDF

Comment on: ‘Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab’ by Eric Morand et al
  1. David Isenberg
  1. Centre for Rheumatology Research, Division of Medicine, UCL, London WC1E 6BT, UK
  1. Correspondence to Professor David Isenberg, Centre for Rheumatology Research, Division of Medicine, UCL, London WC1E 6BT, UK; d.isenberg{at}

Statistics from

I read with great interest the paper by Eric Morand and colleagues1 reporting on the utility of the Lupus Low Disease Activity State attainment using a useful form of discrimination in the phase IIb MUSE Anifrolumab trial published recently in the journal. The manuscript makes a useful contribution to this important debate but does contain one important error which should be corrected.

In the discussion, the authors state ‘The assumption that gastrointestinal activity, which is not measured in the SLEDAI-2K or BILAG…’ is simply incorrect. British Isles Lupus Assessment Group (BILAG)-20042 has a whole section dedicated to capturing gastrointestinal disease. It is one of several facets of lupus activity captured in BILAG but not captured in SLEDAI-2K (others include haemolytic anaemia and ophthalmic disease).



  • Handling editor Josef Smolen

  • Contributors DI is the sole author of this letter.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles